1. Market Research
  2. > Therapy
17 reports for Salicylic Acid (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

Vaginal Cancer - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer – Pipeline Review, H1 2020, provides an overview of the Vaginal Cance ...

  • Cancer Immunotherapy
  • Lung Cancer
  • Sexually Transmitted Disease
  • North America
  • United States

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

Aspirin and Rintatolimod With or Without Interferon-alpha ##b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT## - authorized by the FDA and Roswell Park s Internal Review Board; not yet recruiting), and Chemokine Modulation Therapy and Pembrolizumab in Treating Partic

  • Cancer Immunotherapy
  • Lung Cancer
  • Pharmaceutical
  • Salicylic Acid
  • Therapy

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

Aspirin and Rintatolimod With or Without Interferon-alpha ##b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT## - authorized by the FDA and Roswell Park s Internal Review Board; not yet recruiting), and Chemokine Modulation Therapy and Pembrolizumab in Treating Partic

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Salicylic Acid
  • United States

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • $ 4995
  • December 2016
  • 133 pages

For example, non-steroidal antiinflammatory drugs, opioids and non-opioid analgesics are used to treat pain that arises in a significant portion of ALS patients, and a number of antidepressants and antipsychotics are used to treat the mental symptoms of the condition.

  • Cancer Immunotherapy
  • Clinical Trial
  • Dementia
  • Therapy
  • Biogen Idec Inc.

Sepsis - Pipeline Review, H1 2019

  • $ 2000
  • April 2019
  • 320 pages

NA : Not Available Source: Global Markets Direct NOSO-## - DRUG PROFILE OTP-## - DRUG PROFILE OTP-## - DRUG PROFILE PEPTIDE TO AGONIZE GHSR FOR ACUTE ISCHEMIC STROKE, ACUTE RADIATION SYNDROME AND SEPSIS - DRUG PROFILE PHYSOSTIGMINE SALICYLATE - DRUG PROFILE PNEUMOCOCCAL VACCINE - DRUG PR

  • Blood Disease
  • Cancer Immunotherapy
  • Pharmaceutical
  • Salicylic Acid
  • Therapy

Medulloblastoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 346 pages

All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent.

  • Cancer Immunotherapy
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Meningioma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 349 pages

Aspirin and Rintatolimod With or Without Interferon-alpha ##b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT## - authorized by the FDA and Roswell Park s Internal Review Board; not yet recruiting), and Chemokine Modulation Therapy and Pembrolizumab in Treating Partic

  • Cancer Immunotherapy
  • Chemotherapy
  • Lung Cancer
  • Salicylic Acid
  • Therapy

Oropharyngeal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 485 pages

Aspirin and Rintatolimod With or Without Interferon-alpha ##b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT## - authorized by the FDA and Roswell Park s Internal Review Board; not yet recruiting), and Chemokine Modulation Therapy and Pembrolizumab in Treating Partic

  • Cancer Immunotherapy
  • Lung Cancer
  • Salicylic Acid
  • Therapy
  • United States

Nasopharyngeal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • February 2020
  • 688 pages

Aspirin and Rintatolimod With or Without Interferon-alpha ##b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT## - authorized by the FDA and Roswell Park s Internal Review Board; not yet recruiting), and Chemokine Modulation Therapy and Pembrolizumab in Treating Partic

  • Cancer
  • Cancer Immunotherapy
  • Salicylic Acid
  • Therapy
  • United States

Ependymoma - Pipeline Review, H1 2018

  • $ 2000
  • March 2018
  • 149 pages

Ependymoma - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H1 2018, provides an overview of the Ependymoma ...

  • Cancer Immunotherapy
  • Targeted Therapy
  • Therapy
  • United States
  • Bristol-Myers Squibb Company

Medulloblastoma - Pipeline Review, H1 2020

  • $ 2000
  • June 2020
  • 380 pages

All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent.

  • Cancer Immunotherapy
  • Hospital
  • Pharmaceutical
  • Targeted Therapy
  • Therapy

Pontine Glioma - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 469 pages

All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent.

  • Cancer Immunotherapy
  • Hospital
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

Anal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • November 2019
  • 475 pages

Aspirin and Rintatolimod With or Without Interferon-alpha ##b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT## - authorized by the FDA and Roswell Park s Internal Review Board; not yet recruiting), and Chemokine Modulation Therapy and Pembrolizumab in Treating Partic

  • Cancer
  • Cancer Immunotherapy
  • Chemotherapy
  • Hospital
  • Therapy

Pontine Glioma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 438 pages

All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent.

  • Cancer Immunotherapy
  • Hospital
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 385 pages

ASPIRIN AND RINTATOLIMOD WITH OR WITHOUT INTERFERON-ALPHA ##B IN TREATING PATIENTS WITH PROSTATE CANCER BEFORE SURGERY (NCT NCT## - AUTHORIZED BY THE FDA AND ROSWELL PARK S INTERNAL REVIEW BOARD; NOT YET RECRUITING), AND CHEMOKINE MODULATION THERAPY AND PEMBROLIZUMAB IN TREATING PARTIC

  • Cancer Immunotherapy
  • Hospital
  • Pharmaceutical
  • Salicylic Acid
  • Therapy

Nasopharyngeal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 596 pages

ASPIRIN AND RINTATOLIMOD WITH OR WITHOUT INTERFERON-ALPHA ##B IN TREATING PATIENTS WITH PROSTATE CANCER BEFORE SURGERY (NCT NCT## - AUTHORIZED BY THE FDA AND ROSWELL PARK S INTERNAL REVIEW BOARD; NOT YET RECRUITING), AND CHEMOKINE MODULATION THERAPY AND PEMBROLIZUMAB IN TREATING PARTIC

  • Cancer
  • Cancer Immunotherapy
  • Hospital
  • Salicylic Acid
  • Therapy

Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

  • $ 1500
  • October 2016
  • 118 pages

It is a salicylic acid derivative with potential antineoplastic activity.

  • Cancer Immunotherapy
  • Pharmaceutical
  • Salicylic Acid
  • Therapy
  • Ono Pharmaceutical Co., Ltd.


View report >

Hormone Market in Oklahoma (USA)

  • October 2018
  • 210 pages

Prescriber must document that the member is not taking > ##mg of aspirin per day and that the member is not taking any epoxide hydrolase inhibitors; and ##.

  • Cancer Immunotherapy
  • Healthcare
  • Hormone
  • Salicylic Acid
  • Targeted Therapy

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on